Renaissance Technologies (RenTech)'s ZNTL Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 2.88 M shares of Zentalis Pharmaceuticals, Inc. (ZNTL) worth $3.89 M, representing 0.01% of the portfolio. First purchased in 2020-Q4, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ZNTL, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 795,802 shares. Largest reduction occurred in Q2 2022, reducing 109,337 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Zentalis Pharmaceuticals (ZNTL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Zentalis Pharmaceuticals (ZNTL) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +558,390 | Add 24.01% | 2.88 M | $1.35 |
| Q3 2025 | +795,802 | Add 52.03% | 2.33 M | $1.51 |
| Q2 2025 | +703,512 | Add 85.17% | 1.53 M | $1.16 |
| Q1 2025 | +286,696 | Add 53.16% | 826,041 | $1.59 |
| Q4 2024 | -17,599 | Reduce 3.16% | 539,345 | $3.03 |
| Q3 2024 | -104,738 | Reduce 15.83% | 556,944 | $3.68 |
| Q2 2024 | +399,745 | Add 152.61% | 661,682 | $4.09 |
| Q1 2024 | -47,340 | Reduce 15.31% | 261,937 | $15.76 |
| Q4 2023 | +23,840 | Add 8.35% | 309,277 | $15.15 |
| Q3 2023 | +75,000 | Add 35.64% | 285,437 | $20.06 |
| Q2 2023 | +177,700 | Add 542.81% | 210,437 | $0.03 |
| Q1 2023 | +32,737 | New Buy | 32,737 | $0.02 |
| Q2 2022 | -109,337 | Sold Out | 0 | $0.00 |
| Q1 2022 | +109,337 | New Buy | 109,337 | $46.14 |
| Q4 2021 | -31,337 | Sold Out | 0 | $0.00 |
| Q3 2021 | +31,337 | New Buy | 31,337 | $66.63 |
| Q1 2021 | -6,397 | Sold Out | 0 | $0.00 |
| Q4 2020 | +6,397 | New Buy | 6,397 | $51.90 |
Renaissance Technologies (RenTech)'s Zentalis Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Zentalis Pharmaceuticals, Inc. (ZNTL) in Q4 2020, acquiring 6,397 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Zentalis Pharmaceuticals, Inc. (ZNTL) for 18 quarters since Q4 2020.
Renaissance Technologies (RenTech)'s largest addition to Zentalis Pharmaceuticals, Inc. (ZNTL) was in Q3 2025, adding 2,325,355 shares worth $3.51 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 2,883,745 shares of Zentalis Pharmaceuticals, Inc. (ZNTL), valued at approximately $3.89 M.
As of the Q4 2025 filing, Zentalis Pharmaceuticals, Inc. (ZNTL) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Zentalis Pharmaceuticals, Inc. (ZNTL) was 2,883,745 shares, as reported at the end of Q4 2025.